Lonza (LON:0QNO) and South Korea-based ABL Bio (KOSDAQ:298380) have joined forces to accelerate bispecific antibody development for immuno-oncology and neurodegenerative diseases. Over email, Basel, Switzerland–headquartered Lonza noted that its experience with novel molecular formats enables the company to handle ABL Bio’s unique challenges. In the partnership, Lonza will provide submission-ready chemistry, manufacturing and controls (CMC) data…
Prominent cell and gene therapy vendors in 2023
In recent years, the cell and gene therapy market has grown at a rapid clip. The momentum is likely to continue. According to Vision Research Reports, the global cell and gene therapy market size could hit around $42.56 billion by 2030, growing at a CAGR of 39% from 2022 to 2030. The burgeoning demand in…
Q&A: Getting solid form selection right in early drug development
A significant milestone in early pharmaceutical development is the selection of the lead solid form. This step can be tricky, however, because about 90% of organic molecules have multiple forms. But problems at this stage can spell trouble down the line for drug candidates’ manufacturability, stability and bioavailability. Because many smaller drug developments don’t have…